Reporting from the Triple ENA conference, JPMorgan said updates from Revolution Medicines for RMC-6236 and RMC-6291 “continue to impress us on several fronts.” While the upcoming ESMO presentation “remains the key catalyst” for RMC-6236 and for the shares, the Triple presentation confirmed the scope of the data that should be expected at ESMO, says the analyst, who keeps an Overweight rating and $41 price target on Revolution shares.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on RVMD:
- Revolution Medicines RMC-6291, RMC-6236 safety data look ‘great,’ says Stifel
- Revolution Medicines Presents Encouraging Clinical Data for RMC-6236 and RMC-6291 at 2023 Triple Meeting
- Revolution’s RMC-6291 abstract ‘reads well on efficacy,’ says Stifel
- Revolution Medicines shares jump 13%, or $3.41, to $28.96
- JPMorgan biotech analysts hold an analyst/industry conference call
